School of Medicine


Showing 1-18 of 18 Results

  • Lucia Aronica

    Lucia Aronica

    Postdoctoral Research Fellow, Stanford Cancer Center

    Bio Until now, most medical treatments have been designed for the “average patient.” As a result of this “one-size-fits-all” approach, treatments can be very successful for some patients but not for others. Precision Medicine, on the other hand, is an innovative approach that takes into account individual differences in people’s genes, environments, and lifestyles. The interaction between genetic, environmental and lifestyle factors is called epigenetics.

    My research investigates the role of epigenetic changes in obesity and weight-loss to design precision-medicine solutions that are tailored to people’s unique characteristics. To this end I am studying how obesity and weight loss modify our epigenetic landscape, and how these changes interact with genetic and lifestyle factors to predict disease status and reversal for the design of personalized medicine strategies. My ultimate goal is to change the very nature of health care—true patient-centered care based upon prediction and prevention rather than relying exclusively on diagnosis and treatment.

    For this project I have been awarded a Marie-Curie Fellowship, Europe’s most competitive research grant, scoring #1 among the applicants in the entire Life Sciences panel. Previously, I received a Hertha Firnberg award from the Austrian Science Funds, and became project leader at the Vienna-Biocenter in Austria. I have also received science communication awards from Europe PubMed Central and FameLab International. I have research experience from the University of Oxford, University Federico II of Naples, University of Vienna, University of Southern California, and Stanford University. I have published research papers in top-ranked peer reviewed journals such as Cell, Genes and Development, the EMBO Journal and Nucleic Acid Research.

  • Zheng Hu

    Zheng Hu

    Postdoctoral Research Fellow, Stanford Cancer Center

    Current Research and Scholarly Interests My interest is applying population genetics approaches to the study of tumor evolution and dynamics with focus on the principles of intratumour heterogeneity, tumor progression, origin of metastasis and drug resistance etc.

  • Yusuke Nakauchi M.D., Ph.D.

    Yusuke Nakauchi M.D., Ph.D.

    Postdoctoral Research Fellow, Stanford Cancer Center

    Current Research and Scholarly Interests From 2005 to 2010, my work as a clinical hematology fellow allowed me to experience first-hand how scientific advances that started in a laboratory can transform the lives of patients. While many of my patients were cured of their disease with allogeneic hematopoietic stem cell transplantation, underscoring the importance of anti-tumor immunotherapy in eradicating leukemia, I witnessed face-to-face their suffering from the long-term consequence of graft-versus-host disease (GVHD). This experience was ultimately what drove me to engage in research to discover novel therapies. For this reason, I embarked on a PhD program in 2010 to design antibody therapy to (i) target GVHD and (ii) target hematological malignancies. Under the mentorship of Professor Hiromitsu Nakauchi at the University of Tokyo, an international leader in hematopoiesis, I developed allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies for severe GVHD caused by HLA-mismatched hematopoietic stem cell transplantation (Nakauchi et al., Exp Hematol, 2015). This study was the first to find that anti-HLA antibodies can be used therapeutically against GVHD. That success gave me the motivation and confidence to further my research beyond targeting GVHD, to targeting leukemic stem cells through my current postdoctoral fellowship in the laboratory of Professor Ravindra Majeti, Department of Hematology at Stanford University.

    Many people suffer from leukemia each year, but we still don’t know how to completely cure it. Recent advances in sequencing technologies have tremendously improved our understanding of the underlying mutations that drive hematologic malignancies, although, the reality is that the majority of the mutations are not easily “druggable” and the discovery of these mutations has not yet made a significant impact in patient outcomes. I view this perhaps the most crucial challenges facing a translational cancer researcher like myself. My current research is a major step toward my long term goal to make personalized medicine a reality for patients with acute myeloid leukemia (AML) and other hematologic malignancies. Although my research is focused on targeting Ten-Eleven Translocation methylcytosine dioxygenase-2 (TET2) mutations, I anticipate it will lead to a better understanding of the cell context requirement for TET2 mutations in AML and help identify the critical cells to target to both prevent the development of de novo leukemia and halt relapse. It may also prove of value to understanding of the biology of a range of other cancers.

  • Daniel Thomas

    Daniel Thomas

    Postdoctoral Research Fellow, Stanford Cancer Center

    Current Research and Scholarly Interests Whilst cancer is first a disease of unregulated cell proliferation, a small proportion of cells within a tumour are paradoxically in a relative state of quiescence. These chemotherapy-resistant cells are the likely culprits responsible for relapse but the signalling events that control this state are unknown. By studying purified populations of cancer stem cells derived from patients with acute myeloid leukemia my work is focused on defining novel targets for future therapy.